Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Cancer of Prostate

lutetium has been researched along with Cancer of Prostate in 99 studies

Research

Studies (99)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (15.15)29.6817
2010's52 (52.53)24.3611
2020's32 (32.32)2.80

Authors

AuthorsStudies
Boros, E; Cingoranelli, SJ; Lapi, SE; Loveless, CS; Schlyer, D; Vaughn, BA1
Mumtaz, M; Shahid, A; Sheikh, N; Younis, MN1
Burkett, BJ1
Balieiro, LM; Benedetto, R; Bortoleti de Araújo, E; Brandão Freire, MR; de Jesus Silva, J; de Queiroz Souza Passos, P; Ferreira Dos Santos, CS; Marumo, MH; Pereira Dias, LA; Teixeira, LFS; Vieira, DP; Vivaldini, BF; Wieczorek Villas Boas, CA1
Hindié, E1
Kashihara, K; Kashihara, T1
Berruti, A; Dalla Volta, A; Grisanti, S1
Kraus, BJ; Morris, MJ; Sartor, O1
Alexoff, D; Choi, SR; Kung, HF; Li, L; Ploessl, K; Yao, X; Zha, Z; Zhao, R; Zhu, L1
Almaguel, F; Armstrong, E; Chin, BB; Flavell, RR; Gayed, IW; Ippisch, RC; Morley, A; Pantel, AR; Parent, EE; Savir-Baruch, B1
Boughdad, S; Digklia, A; Dolcan, A; Dromain, C; Homicsko, K; Peters, S; Prior, J; Schaefer, N; Trimech, M1
Karnes, RJ; Kemble, J; Kwon, ED1
de Bakker, M; Dominicus, N; Janssen, M; Konijnenberg, MW; Meeuwis, A; Nagarajah, J; Peters, SMB1
Crowley, JR1
Baum, R; Bodei, L; Bozkurt, MF; Czernin, J; Delgado Bolton, RC; Eiber, M; Ezziddin, S; Fanti, S; Fendler, WP; Forrer, F; Haberkorn, U; Herrmann, K; Hicks, RJ; Hope, TA; Kabasakal, L; Konijnenberg, M; Kopka, K; Kratochwil, C; Lassmann, M; Mottaghy, FM; Oyen, W; Rahbar, K; Schöder, H; Virgolini, I; Wester, HJ1
Azad, A; Hofman, MS; Iravani, A; Violet, J1
Flechsig, P; Giesel, FL; Haberkorn, U; Hohenfellner, M; Holland-Letz, T; Kopka, K; Kratochwil, C; Mavriopoulou, E; Mier, W; Rathke, H; Röhrich, M1
Taneja, SS1
Akbarian, R; Fattahi, K; Ghodsirad, MA; Javanmard, B; Kaghazchi, F; Pirayesh, E; Tavakoli, M1
Allen, JC; Kanesvaran, R; Lam, WWC; Ler, ASL; Ng, DCE; Somanesan, S; Tay, YS; Thang, SP; Tong, AKT; Wong, ASC1
Bögemann, M; Herrmann, K; Radtke, JP; Rahbar, K1
Dahlbom, M; Reiter, RE; Tsai, WK; Wu, AM; Zettlitz, KA1
Pirayesh, E1
Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M1
Bolzati, C; Duatti, A1
Dalm, SU; de Blois, E; de Jong, M; de Ridder, C; Haeck, J; Konijnenberg, MW; Nonnekens, J; Ruigrok, EAM; Stuurman, D; van Gent, DC; van Vliet, N; van Weerden, WM1
Grobbee, DE; Hehakaya, C; Lam, MGEH; Moors, EHM; Verburg, FA; Verkooijen, HM1
Tagawa, ST1
Civan, C; Ekenel, M; Has Simsek, D; Kuyumcu, S; Sanli, Y1
Das, N; Goyal, S; Madan, R; Mittal, BR; Satapathy, S; Singh, SK; Sood, A1
de Bakker, M; de Lange, F; Eek, A; Gotthardt, M; Jentzen, W; Konijnenberg, MW; Mehra, N; Muselaers, CHJ; Nagarajah, J; Peters, SMB; Privé, BM; Witjes, JA1
Alghazo, O; Buteau, J; Cumberbatch, M; Eapen, R; Koschel, S; Lawrentschuk, N; Loh, R; Murphy, DG1
Ahmadzadehfar, H; Becker, A; Eppard, E; Essler, M; Feldmann, G; Fisang, C; Kürpig, S; Yordanova, A1
Anderson, CJ; Berkman, CE; Beyer, SK; Choy, CJ; Geruntho, JJ; Langton-Webster, B; Latoche, JD; Ling, X1
Eiber, M; Fendler, WP; Herrmann, K; Kratochwil, C; Rahbar, K1
Acar, O; Demirkol, MO; Esen, T; Falay, O; Kiremit, MC; Ucar, B1
Ferdinandus, J; Hofman, MS; Sandhu, S; Violet, J1
Kumar, R; Mittal, BR; Parihar, AS; Singh, SK; Vadi, SK1
Turner, JH1
Assam, I; Jüptner, M; Lützen, U; Zuhayra, M1
Chakraborty, S; Chakravarty, R; Dash, A; Sarma, HD; Vimalnath, KV1
Baum, RP; Kulkarni, HR; Langbein, T; Lehmann, C; Mueller, D; Schuchardt, C; Singh, A; Zhang, J1
Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z1
Ferretti, A; Gross, MD; Rubello, D; Viglianti, BL; Wale, DJ; Wong, KK1
Cooperberg, M; Eapen, RS; Hofman, MS; Lawrentschuk, N; Murphy, DG; Nzenza, TC1
D'Alessandria, C; Eiber, M; Gafita, A; Heck, M; Knorr, K; Rauscher, I; Retz, M; Tauber, R; Weber, WA; Wester, HJ1
Ahmadzadehfar, H; Essler, M; Feldmann, G; Gaertner, FC; Hauser, S; Kürpig, S; Linden, P; Meisenheimer, M; Yordanova, A1
Aranda-Lara, L; Azorín-Vega, E; Ferro-Flores, G; Jiménez-Mancilla, N; Nava-Cabrera, MA; Rojas-Calderón, E1
Escudero-Castellanos, A; Ferro-Flores, G; Isaac-Olivé, K; Luna-Gutiérrez, M; Morales-Ávila, E; Ocampo-García, B; Santos-Cuevas, C1
Eberlein, U; Lapa, C; Lassmann, M; Muhtadi, R; Scherthan, H; Schumann, S; Serfling, S1
Acar, E; Aksu, A; Bekiş, R; Çapa Kaya, G; Derebek, E; Özdoğan, Ö1
Burger, IA; Deberle, LM; Eberli, D; Hermanns, T; Kranzbühler, B; Müller, C; Salemi, S; Sulser, T; Umbricht, CA1
Antonarakis, ES; Denmeade, SR; Eisenberger, MA; Eshleman, JR; Isaacsson Velho, P; Luo, J; Paller, CJ; Piana, D; Pomper, MG; Riel, S; Rowe, SP1
Batra, SK; Fan, W; Garrison, JC; Lele, SM; Rachagani, S; Zhang, W; Zhou, Z1
Borkowski, S; Braun, F; Dumont, RA; Maecke, H; Mansi, R; Reubi, JC; Tamma, M; Weber, WA1
Bao, A; Cheng, Z; Cutler, CS; Jiang, L; Liu, H; Miao, Z; Ren, G; Shi, H1
Huxol, E; Mindt, TL; Valverde, IE1
Brandt-Larsen, M; Juhl, K; Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P1
Breeman, WA; de Blois, E; de Jong, M; Krenning, EP; Maina, T; Marsouvanidis, PJ; Melis, M; Nock, BA1
Cho, EH; Choi, SM; Kim, JJ; Lee, Sy; Lim, JC; Nam, SS; Park, SH; Park, UJ2
Afshar-Oromieh, A; Bauder-Wüst, U; Benešová, M; Eder, M; Haberkorn, U; Kopka, K; Kratochwil, C; Mier, W; Schäfer, M1
Baum, RP; Beykan, S; Eiber, M; Klette, I; Kulkarni, HR; Lassmann, M; Schottelius, M; Schwaiger, M; Simecek, J; Weineisen, M; Wester, HJ; Yildiz, A1
Akyurek, S; Kucuk, NO; Ozkan, E; Soydal, C1
Knapp, FF; Pillai, AM1
Elgqvist, J; Larsson, E; Strand, SE; Timmermand, OV1
Dietlein, M; Drzezga, A; Eschner, W; Fischer, T; Hohberg, M; Kobe, C; Schmidt, M; Wild, M1
Ahmadzadehfar, H; Bode, A; Claesener, M; Eppard, E; Heinzel, A; Rahbar, K; Schmidt, M; Yordanova, A1
Abuqbeitah, M; Çavdar, İ; Demir, M; Gündüz, H; Kabasakal, L; Uslu-Beşli, L; Vatankulu, B; Yeyin, N; Yıldırım, Ö1
Banerjee, S; Das, T; Guleria, M; Kale, C; Lele, VR; Parab, A; Sarma, HD; Shah, H1
Chakraborty, S; Chakravarty, R; Dash, A; Sen, IB; Shetty, P; Vimalnath, KV1
Banerjee, S; Das, T; Guleria, M1
Baum, RP; Beer, AJ; Glatting, G; Kletting, P; Kulkarni, HR; Schuchardt, C; Shahinfar, M; Singh, A1
Ahmadzadehfar, H; Essler, M; Rahbar, K; Schäfers, M1
Ahmadzadehfar, H; Bartenstein, P; Baum, RP; Bögemann, M; Brenner, W; Drzezga, A; Essler, M; Eveslage, M; Fendler, WP; Haberkorn, U; Heinzel, A; Heuschkel, M; Kratochwil, C; Krause, BJ; Kulkarni, HR; Luster, M; Lützen, U; Marx, M; Meyer, PT; Mottaghy, FM; Pfestroff, A; Prasad, V; Rahbar, K; Ruf, J; Schäfers, M; Schmidt, M1
Eiber, M; Herrmann, K1
Eiber, M; Heck, MM; Knorr, K; Kratochwil, C; Retz, M; Tauber, R1
Blanksby, A; Emmett, L; Lee, J; Shin, J; Violet, J; Willowson, K1
Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE1
Tweedle, MF1
Bander, NH; Beltran, H; Goldsmith, SJ; Matulich, D; Nanus, DM; Osborne, J; Parmar, S; Petrillo, K; Tagawa, ST; Vallabhajosula, S1
Chang, CH; Chang, TJ; Chen, LC; Chiu, SP; Chuang, CH; Fu, YK; Ho, CL; Lee, TW; Lee, WC; Liu, IH; Wu, YH1
Boisclair, J; Bruchertseifer, F; Frischknecht, M; Maecke, HR; Morgenstern, A; Provencher-Bolliger, A; Reubi, JC; Wild, D; Zhang, H1
Couto, RM; De Araújo, EB; Grallert, SR; Melero, LT; Mengatti, J; Pujatti, PB; Santos, JS; Soares, CR; Suzuki, MF1
Goldsmith, SJ; Joyce, MA; Kostakoglu, L; Liu, H; Milowsky, M; Nanus, DM; Trabulsi, EJ; Vallabhajosula, S; Yao, D1
Eberwein, DJ; Ingram, AC; Knick, VC; Murray, DM; Ryan, CH; Stimmel, JB; Thurmond, LM; Witherspoon, SM1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabahajosula, S1
Chen, J; Hinni, K; Maecke, HR; Reubi, JC; Waldherr, C; Waser, B; Zhang, H1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Kothari, PA; Kuji, I; Milowski, MI; Nanus, DM; Vallabhajosula, S1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S2
Scott, AM1
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S1
Hoffman, TJ; Johnson, CV; Ma, L; Perry, MC; Shelton, T; Smith, CJ; Volkert, WA1
Arunachalam, T; Bogdan, NJ; Cappelletti, E; Chen, J; Eaton, SM; Feng, W; Fox, JS; Lantry, LE; Lattuada, L; Linder, KE; Maddalena, ME; Metcalfe, EC; Nunn, AD; Raju, N; Reubi, JC; Swenson, RE; Thomas, R; Tweedle, MF1
Eisenhut, M; Maecke, HR; Reubi, JC; Schuhmacher, J; Waser, B; Wild, D; Zhang, H1
Cutler, CS; Hoffman, T; Hu, F; Jurisson, SS; Sieckman, G; Volkert, WA1

Reviews

15 review(s) available for lutetium and Cancer of Prostate

ArticleYear
    Journal of nuclear medicine technology, 2022, Volume: 50, Issue:3

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals

2022
Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
    Expert review of anticancer therapy, 2023, Volume: 23, Issue:2

    Topics: Carcinoma, Neuroendocrine; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Male; Membrane Proteins; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes

2023
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
    Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:1

    Topics: Combined Modality Therapy; Dipeptides; Disease Management; Drug Administration Schedule; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Molecular Imaging; Molecular Targeted Therapy; Neoplasm Staging; Patient Selection; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Theranostic Nanomedicine; Treatment Outcome

2020
[PSMA radioligand therapy in patients with advanced prostate cancer].
    Der Urologe. Ausg. A, 2020, Volume: 59, Issue:6

    Topics: Dipeptides; Germany; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome

2020
The emerging value of 64Cu for molecular imaging and therapy.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2020, Volume: 64, Issue:4

    Topics: Antigens, Surface; Chelating Agents; Coordination Complexes; Copper Radioisotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Iodine Radioisotopes; Lutetium; Male; Molecular Imaging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin

2020
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:8

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Prostatic Neoplasms; Radioisotopes; Radiotherapy; Safety

2017
Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Current opinion in urology, 2018, Volume: 28, Issue:2

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Prostate; Prostatic Neoplasms; Radioisotopes; Theranostic Nanomedicine; Treatment Outcome

2018
Recent advances in theranostics and challenges for the future.
    The British journal of radiology, 2018, Volume: 91, Issue:1091

    Topics: Clinical Trials as Topic; Dipeptides; Forecasting; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Molecular Targeted Therapy; Neuroendocrine Tumors; Peptides, Cyclic; Prostate-Specific Antigen; Prostatic Neoplasms; Radioactive Tracers; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Theranostic Nanomedicine

2018
Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
    The British journal of radiology, 2018, Volume: 91, Issue:1091

    Topics: Aged; Dipeptides; Edetic Acid; Forecasting; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Oligopeptides; Positron Emission Tomography Computed Tomography; Precision Medicine; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Theranostic Nanomedicine

2018
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium

2019
PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
    World journal of urology, 2019, Volume: 37, Issue:7

    Topics: Dipeptides; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Membrane Glycoproteins; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Theranostic Nanomedicine

2019
[PSMA-targeted radioligand therapy in prostate cancer].
    Der Urologe. Ausg. A, 2017, Volume: 56, Issue:1

    Topics: Antigens, Surface; Dipeptides; Evidence-Based Medicine; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Molecular Targeted Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Treatment Outcome

2017
Lutetium
    Journal of medical radiation sciences, 2017, Volume: 64, Issue:1

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Prostatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Safety

2017
The utility of monoclonal antibodies in the imaging of prostate cancer.
    Seminars in urologic oncology, 2002, Volume: 20, Issue:3

    Topics: Antibodies, Monoclonal; Antigens, Surface; Carboxypeptidases; Glutamate Carboxypeptidase II; Humans; Indium Radioisotopes; Lutetium; Male; Prostatic Neoplasms; Radiography; Radioisotopes; Tomography, Emission-Computed

2002
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
    Seminars in oncology, 2003, Volume: 30, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antigens, Surface; Clinical Trials, Phase I as Topic; Cytotoxins; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Extracellular Space; Fluorescent Antibody Technique; Glutamate Carboxypeptidase II; Humans; Immunoglobulin G; Lutetium; Male; Mice; Prostatic Neoplasms; Radioimmunodetection; Radioisotopes; Treatment Outcome; Yttrium Radioisotopes

2003

Trials

6 trial(s) available for lutetium and Cancer of Prostate

ArticleYear
Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population.
    Nuclear medicine communications, 2020, Volume: 41, Issue:7

    Topics: Adult; Aged; Asian People; Humans; Kallikreins; Lutetium; Male; Middle Aged; Pain; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Survival Analysis; Treatment Outcome

2020
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
    Nuklearmedizin. Nuclear medicine, 2020, Volume: 59, Issue:6

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome

2020
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:4

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Half-Life; Humans; Indium Radioisotopes; Lutetium; Male; Metabolic Clearance Rate; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Relative Biological Effectiveness; Tissue Distribution; Yttrium Radioisotopes

2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-20, Volume: 23, Issue:21

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Cell Membrane; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging

2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Bone Marrow; Bone Marrow Diseases; Dose-Response Relationship, Radiation; Humans; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Yttrium Radioisotopes

2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 2

    Topics: Antibodies, Monoclonal; Blood Platelets; Bone Marrow; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Lutetium; Male; Maximum Tolerated Dose; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Thrombocytopenia; Time Factors; Yttrium Radioisotopes

2005

Other Studies

78 other study(ies) available for lutetium and Cancer of Prostate

ArticleYear
Evaluation of
    Molecular pharmaceutics, 2021, 12-06, Volume: 18, Issue:12

    Topics: Animals; Chelating Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Scandium; Tissue Distribution

2021
Tc-99m PSMA and Lu-177 PSMA Theranostic Pair in a Patient of Metastatic Castration Resistant Prostate Cancer.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71, Issue:11

    Topics: Humans; Lutetium; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes

2021
Radioligand Therapy for Metastatic Prostate Cancer.
    Radiology. Imaging cancer, 2021, Volume: 3, Issue:6

    Topics: Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Prostatic Neoplasms

2021
In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177.
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2022, Volume: 180

    Topics: Animals; Cell Line, Tumor; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Mice, SCID; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays

2022
Lutetium-177-PSMA-617 for Prostate Cancer.
    The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes

2021
Lutetium-177-PSMA-617 for Prostate Cancer.
    The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes

2021
Lutetium-177-PSMA-617 for Prostate Cancer.
    The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes

2021
Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    The New England journal of medicine, 2021, 12-23, Volume: 385, Issue:26

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes

2021
New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
    Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19

    Topics: Albumins; Animals; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Edetic Acid; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Mice; Prostatic Neoplasms; Radioisotopes; Tissue Distribution

2022
First communication on the efficacy of combined
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:10

    Topics: Communication; Humans; Immunotherapy; Lutetium; Male; Prostate; Prostatic Neoplasms; Radioisotopes

2022
Lutetium lu 177 vipivotide tetraxetan (Pluvicto) for prostate cancer.
    The Medical letter on drugs and therapeutics, 2022, 12-12, Volume: 64, Issue:1665

    Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms

2022
Urinary excretion kinetics of [
    European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:12

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals

2023
Critical Challenges in Pluvicto Therapy: Incontinent and Anticoagulated Patients.
    Journal of nuclear medicine technology, 2023, Dec-05, Volume: 51, Issue:4

    Topics: Humans; Lutetium; Male; Precision Medicine; Prostatic Neoplasms

2023
EANM procedure guidelines for radionuclide therapy with
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:12

    Topics: Antigens, Surface; Documentation; Europe; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Nuclear Medicine; Practice Guidelines as Topic; Prostatic Neoplasms; Radioisotopes; Radiometry; Safety

2019
Response Prediction of
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:5

    Topics: Aged; Biomarkers, Tumor; Chromogranin A; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; L-Lactate Dehydrogenase; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

2020
Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (
    The Journal of urology, 2020, Volume: 203, Issue:5

    Topics: Dipeptides; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Theranostic Nanomedicine

2020
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
    Urology journal, 2020, 06-23, Volume: 17, Issue:4

    Topics: Aged; Aged, 80 and over; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon

2020
Evaluation of [
    Molecular imaging and biology, 2020, Volume: 22, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Radiation; GPI-Linked Proteins; Iodine Radioisotopes; Lutetium; Male; Mice; Neoplasm Proteins; Pentetic Acid; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Radiometry; Survival Analysis; Tissue Distribution

2020
Radioligand Therapy With 177Lu-Prostate-Specific Membrane Antigen in a Patient With Non-Prostate-Specific Antigen-Secreting Metastatic Prostate Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:10

    Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Treatment Outcome

2020
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 48, Issue:5

    Topics: Animals; Antigens, Surface; Cell Line, Tumor; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Mice; Prostatic Neoplasms; Radioisotopes; Tissue Distribution

2021
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 48, Issue:8

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant

2021
PSMA-targeted therapy in prostate cancer.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Antibodies, Bispecific; Antibodies, Neoplasm; Antigens, Surface; Biomarkers, Tumor; Clinical Trials as Topic; Dipeptides; Docetaxel; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lutetium; Male; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Randomized Controlled Trials as Topic

2021
177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
    Clinical nuclear medicine, 2021, May-01, Volume: 46, Issue:5

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Testicular Neoplasms

2021
Short-course
    European urology, 2021, Volume: 80, Issue:3

    Topics: Aged; Antineoplastic Agents, Hormonal; Humans; Leuprolide; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Treatment Outcome

2021
Intra-therapeutic dosimetry of [
    European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:2

    Topics: Hormones; Humans; Lutetium; Male; Organs at Risk; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dosage; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome

2022
The application of theranostics in different stages of prostate cancer.
    Future oncology (London, England), 2021, Volume: 17, Issue:27

    Topics: Clinical Trials as Topic; Humans; Lutetium; Male; Neoplasm Staging; Precision Medicine; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy

2021
The impact of repeated cycles of radioligand therapy using [
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:9

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Hormones; Humans; Kidney; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Time Factors; Treatment Failure

2017
    Theranostics, 2017, Volume: 7, Issue:7

    Topics: Albumins; Amides; Animals; Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Glutamate Carboxypeptidase II; Heterografts; Humans; Lutetium; Male; Mice; Mice, Nude; Phosphoric Acids; Prostatic Neoplasms; Radioisotopes; Treatment Outcome

2017
Local Salvage Treatment of Post-brachytherapy Recurrent Prostate Cancer via Theranostic Application of PSMA-labeled Lutetium-177.
    Clinical genitourinary cancer, 2018, Volume: 16, Issue:2

    Topics: Administration, Intravenous; Antigens, Surface; Brachytherapy; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Salvage Therapy; Theranostic Nanomedicine; Treatment Outcome

2018
Unusual Case of Diffuse Penile Metastasis of Prostate Cancer on 68Ga PSMA PET/CT Imaging and 177Lu PSMA Posttherapy Scintigraphy.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:4

    Topics: Aged, 80 and over; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lutetium; Male; Oligopeptides; Penile Neoplasms; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radioisotopes

2018
Successful handling of an accidental extravasation of 177Lu-PSMA-617 in the treatment of advanced prostate cancer.
    Nuklearmedizin. Nuclear medicine, 2018, Volume: 57, Issue:2

    Topics: Aged; Dipeptides; Extravasation of Diagnostic and Therapeutic Materials; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Manual Lymphatic Drainage; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals

2018
Multidose formulation of ready-to-use
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2018, Volume: 139

    Topics: Animals; Dipeptides; Drug Compounding; Drug Stability; Drug Storage; Heterocyclic Compounds, 1-Ring; Humans; In Vitro Techniques; Lutetium; Male; Nuclear Pharmacy; Prostate-Specific Antigen; Prostatic Neoplasms; Quality Control; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Rats; Rats, Wistar; Tissue Distribution

2018
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
    Bioconjugate chemistry, 2018, 09-19, Volume: 29, Issue:9

    Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes

2018
Early Experience of Rechallenge
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:5

    Topics: Aged; Cohort Studies; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome

2019
Outcome and safety of rechallenge [
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Dipeptides; Feasibility Studies; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Safety; Survival Analysis; Treatment Outcome

2019
Assessment of the radiation absorbed dose produced by
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2019, Volume: 146

    Topics: Actinium; Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Computer Simulation; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Models, Biological; Monte Carlo Method; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Tumor Microenvironment

2019
Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Nuclear medicine communications, 2019, Volume: 40, Issue:3

    Topics: Animals; Antigens, Surface; Bombesin; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dimerization; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lysine; Male; Mice; Prostatic Neoplasms; Radiochemistry; Radioisotopes; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2019
DNA damage in blood leucocytes of prostate cancer patients during therapy with
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:8

    Topics: Aged; Aged, 80 and over; Dipeptides; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Radiation; Heterocyclic Compounds, 1-Ring; Humans; Leukocytes; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage

2019
The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival.
    Annals of nuclear medicine, 2019, Volume: 33, Issue:9

    Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radioisotopes; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden

2019
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of
    The Prostate, 2019, Volume: 79, Issue:12

    Topics: 5-alpha Reductase Inhibitors; Antigens, Surface; Cell Line, Tumor; Dipeptides; Dose-Response Relationship, Drug; Dutasteride; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Receptors, Androgen; Up-Regulation

2019
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
    The Prostate, 2019, Volume: 79, Issue:14

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome

2019
Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy.
    Scientific reports, 2019, 07-31, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Autoradiography; Disease Models, Animal; Female; Hypoxia; Lutetium; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution

2019
Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:5

    Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Lutetium; Male; Mice; Molecular Targeted Therapy; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Sirolimus

2013
177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
    Nuclear medicine communications, 2013, Volume: 34, Issue:9

    Topics: Animals; Aza Compounds; Bombesin; Cell Line, Tumor; Dimerization; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Molecular Targeted Therapy; Oligopeptides; Prostatic Neoplasms; Radiation Dosage; Radiochemistry; Radioisotopes

2013
Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting.
    Journal of labelled compounds & radiopharmaceuticals, 2014, Volume: 57, Issue:4

    Topics: Amino Acid Sequence; Bombesin; Cell Line, Tumor; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Peptide Fragments; Peptidomimetics; Prostatic Neoplasms; Proteolysis; Radioisotopes; Tomography, Emission-Computed, Single-Photon; Triazoles

2014
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
    Molecular pharmaceutics, 2014, Aug-04, Volume: 11, Issue:8

    Topics: Animals; Cell Line, Tumor; Coordination Complexes; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Inhibitory Concentration 50; Ligands; Lutetium; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Protein Binding; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Treatment Outcome; X-Ray Microtomography

2014
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
    Cancer biotherapy & radiopharmaceuticals, 2014, Volume: 29, Issue:9

    Topics: Animals; Cell Line, Tumor; Gastrin-Releasing Peptide; Glycopeptides; Heterografts; Humans; Lutetium; Male; Mice; Mice, Nude; Neprilysin; Peptide Fragments; Prostatic Neoplasms; Protease Inhibitors; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Bombesin; Tissue Distribution

2014
Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Nuclear medicine and biology, 2015, Volume: 42, Issue:2

    Topics: Amino Acids; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Lutetium; Male; Mice; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Tissue Distribution

2015
Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Nuclear medicine and biology, 2015, Volume: 42, Issue:3

    Topics: Aminobenzoates; Animals; Bombesin; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glycosylation; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:6

    Topics: Animals; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Peptides; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution

2015
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8

    Topics: Aged; Anhydrides; Animals; Antigens, Surface; Cell Line, Tumor; Contrast Media; Coordination Complexes; Female; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Inhibitory Concentration 50; Kinetics; Lutetium; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiometry; Radiotherapy

2015
SNMMI 2015 Image of the Year.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8

    Topics: Antigens, Surface; Awards and Prizes; Baltimore; Dipeptides; Gallium; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; History, 21st Century; Humans; Lutetium; Male; Neoplasm Metastasis; Nuclear Medicine; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Medical

2015
Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:2

    Topics: Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lutetium; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed

2016
Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.
    Current radiopharmaceuticals, 2016, Volume: 9, Issue:1

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals

2016
Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Anticancer research, 2016, Volume: 36, Issue:1

    Topics: Alpha Particles; Americium; Beta Particles; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Radiation; Gamma Rays; Humans; Lutetium; Male; Prostatic Neoplasms; Radiation Tolerance; Radioisotopes

2016
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.
    Molecular imaging and biology, 2016, Volume: 18, Issue:3

    Topics: Aged; Demography; Dose-Response Relationship, Radiation; Humans; Lacrimal Apparatus; Lutetium; Male; Middle Aged; Organometallic Compounds; Organs at Risk; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tissue Distribution; Whole Body Imaging

2016
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome

2016
Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
    Journal of radiological protection : official journal of the Society for Radiological Protection, 2016, Volume: 36, Issue:2

    Topics: Caregivers; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Occupational Exposure; Outpatients; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dosage; Radiation Monitoring; Radiotherapy Dosage; Safety Management; Thermoluminescent Dosimetry; Time Factors; Treatment Outcome

2016
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
    Nuclear medicine and biology, 2016, Volume: 43, Issue:5

    Topics: Animals; Cell Line, Tumor; Dipeptides; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dosage; Rats; Rats, Wistar; Tissue Distribution; Translational Research, Biomedical

2016
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Journal of labelled compounds & radiopharmaceuticals, 2016, Volume: 59, Issue:9

    Topics: Aged; Antigens, Surface; Dipeptides; Drug Stability; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Quality Control; Radiochemistry; Radioisotopes

2016
Formulation of clinical-scale
    Nuclear medicine and biology, 2016, Volume: 43, Issue:12

    Topics: Clinical Trials as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms

2016
Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
    PloS one, 2016, Volume: 11, Issue:9

    Topics: Aged; Antigens, Surface; Computer Simulation; Dose-Response Relationship, Drug; Drug Delivery Systems; Glutamate Carboxypeptidase II; Humans; Kidney; Ligands; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Peptides; Prostatic Neoplasms; Radioisotopes; Retrospective Studies; Salivary Glands

2016
Radioligand therapy with
    Nuclear medicine and biology, 2016, Volume: 43, Issue:12

    Topics: Clinical Trials as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms

2016
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:1

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Causality; Comorbidity; Dipeptides; Germany; Hematologic Diseases; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prevalence; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Treatment Outcome

2017
From NETTER to PETTER: PSMA-Targeted Radioligand Therapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017, Volume: 58, Issue:1

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms

2017
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    The Prostate, 2009, Jan-01, Volume: 69, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays

2009
Peptide-targeted diagnostics and radiotherapeutics.
    Accounts of chemical research, 2009, Jul-21, Volume: 42, Issue:7

    Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Cell Line; ErbB Receptors; Gadolinium; Humans; Lutetium; Male; Molecular Sequence Data; Neoplasms; Oligopeptides; Peptides; Positron-Emission Tomography; Prostatic Neoplasms; Protein Binding; Radiopharmaceuticals; Rats; Receptors, G-Protein-Coupled; Tuftsin

2009
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
    Cancer, 2010, Feb-15, Volume: 116, Issue:4 Suppl

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Lutetium; Male; Mice; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals

2010
Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Animals; Cell Line, Tumor; Humans; Isotope Labeling; Luminescent Measurements; Lutetium; Male; Mice; Mice, SCID; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous

2010
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Cancer research, 2011, Feb-01, Volume: 71, Issue:3

    Topics: Alpha Particles; Animals; Beta Particles; Bismuth; Female; Humans; Lutetium; Male; Mice; Mice, Nude; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Xenograft Model Antitumor Assays

2011
Novel series of (177)Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2011, Volume: 55, Issue:3

    Topics: Animals; Bombesin; Cell Line, Tumor; Drug Stability; Humans; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous

2011
Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism.
    Cancer immunology, immunotherapy : CII, 2003, Volume: 52, Issue:7

    Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Survival; Chromium; Colonic Neoplasms; Epithelial Cell Adhesion Molecule; Female; G2 Phase; Humans; In Vitro Techniques; Lutetium; Male; Mice; Mice, Nude; Mitosis; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine

2003
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Cancer research, 2004, Sep-15, Volume: 64, Issue:18

    Topics: Animals; Bombesin; Drug Stability; Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Male; Pancreatic Neoplasms; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Rats; Receptors, Bombesin; Tissue Distribution; Yttrium Radioisotopes

2004
Radioimmunotherapy of prostate cancer: does tumor size matter?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-20, Volume: 23, Issue:21

    Topics: Antibodies, Monoclonal; Humans; Lutetium; Male; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Yttrium Radioisotopes

2005
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
    Cancer biotherapy & radiopharmaceuticals, 2006, Volume: 21, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Bombesin; Docetaxel; Estramustine; Female; Lutetium; Male; Mice; Mice, SCID; Models, Molecular; Peptide Fragments; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Bombesin; Taxoids; Tumor Protein, Translationally-Controlled 1; Xenograft Model Antitumor Assays

2006
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:7

    Topics: Animals; Binding, Competitive; Bombesin; Cell Line, Tumor; Disease Progression; Gene Expression Regulation; Humans; Lutetium; Male; Mice; Mice, Nude; Oligopeptides; Peptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin

2006
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:8

    Topics: Animals; Bombesin; Cell Line, Tumor; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Neoplasm Transplantation; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Receptors, Bombesin

2007
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).
    Nuclear medicine and biology, 2002, Volume: 29, Issue:4

    Topics: Animals; Bombesin; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Metabolic Clearance Rate; Metals, Rare Earth; Mice; Peptide Fragments; Promethium; Prostatic Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Samarium; Sensitivity and Specificity; Tissue Distribution

2002